Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Cilostazol as a unique antithrombotic agent.

Junichi Kambayashi¹, Yongge Liu, Bing Sun

¹Otsuka Maryland Research Institute, Inc. Rockville, MD 20850, USA. junichik@otsuka.com

Current Pharmaceutical Design

|October 8, 2003

Summary

Cilostazol (CLZ), a phosphodiesterase 3 inhibitor, offers unique antiplatelet and vasodilatory effects by inhibiting adenosine uptake. This mechanism provides antithrombotic benefits with a potentially lower bleeding risk compared to other antiplatelet drugs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

PDV1 and PDV2 Differentially Affect Remodeling and Assembly of the Chloroplast DRP5B Ring.

Plant physiology·2020

Same author

Corrigendum to "Low-background electrochemical biosensor for one-step detection of base excision repair enzyme" [Biosens. Bioelectr. 150 (2020) 11865].

Biosensors & bioelectronics·2020

Same author

Corrigendum to "A dual signal-on photoelectrochemical immunosensor for sensitively detecting target avian viruses based on AuNPs/g-C<sub>3</sub>N<sub>4</sub> coupling with CdTe quantum dots and in situ enzymatic generation of electron donor" [Biosens. Bioelectron. 124-125 (2019) 1-7 Article Number: BIOS10843].

Biosensors & bioelectronics·2020

Same author

ECM1 is an essential factor for the determination of M1 macrophage polarization in IBD in response to LPS stimulation.

Proceedings of the National Academy of Sciences of the United States of America·2020

Same author

Correction: β-arrestin1 Is Critical for the Full Activation of NLRP3 and NLRC4 Inflammasomes.

Journal of immunology (Baltimore, Md. : 1950)·2020

Same author

An optimized double T-DNA binary vector system for improved production of marker-free transgenic tobacco plants.

Biotechnology letters·2020

Area of Science:

Pharmacology
Cardiovascular Medicine

Background:

Cilostazol (CLZ) is a selective phosphodiesterase 3 (PDE3) inhibitor developed for antiplatelet and vasodilatory effects.
CLZ uniquely inhibits adenosine uptake, differentiating it from other PDE3 inhibitors like milrinone.
CLZ is approved for peripheral arterial occlusive disease and intermittent claudication symptoms.

Purpose of the Study:

To review the unique properties of Cilostazol (CLZ).
To highlight CLZ's role as an antiplatelet agent targeting platelets and vascular smooth muscle cells (VSMC).
To emphasize CLZ's synergistic effects with endogenous mediators and its reduced bleeding risk.

Main Methods:

Review of preclinical and clinical studies on Cilostazol (CLZ).
Analysis of CLZ's mechanisms of action, including PDE3 inhibition and adenosine uptake inhibition.

Related Experiment Videos

Comparison of CLZ's antithrombotic and antiplatelet properties with other antiplatelet drugs.

Main Results:

CLZ exhibits unique antithrombotic and vasodilatory properties through novel mechanisms.
CLZ demonstrates synergy with endogenous mediators.
CLZ shows a lowered risk of bleeding compared to other antiplatelet agents.

Conclusions:

Cilostazol (CLZ) possesses distinct antiplatelet and vasodilatory actions.
CLZ's ability to inhibit adenosine uptake contributes to its unique therapeutic profile.
CLZ represents a valuable antiplatelet option with a favorable safety profile regarding bleeding risk.